STOK Stoke Therapeutics Inc.

25.26
+1.36  (+6%)
Previous Close 23.9
Open 23.8
Price To Book 3.54
Market Cap 826,754,167
Shares 32,729,777
Volume 241,280
Short Ratio
Av. Daily Volume 142,328
Stock charts supplied by TradingView

NewsSee all news

  1. Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy

    SAN FRANCISCO, Jan. 8, 2020 /PRNewswire/ -- Today BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Invitae Corporation (NYSE:NVTA) announced that Biogen (NASDAQ:BIIB), Encoded Therapeutics, Neurogene, Praxis Precision

  2. Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference

    Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today

  3. Stoke Therapeutics Added to NASDAQ Biotechnology Index

    Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that it has

  4. Stoke Therapeutics Presents Preclinical Data on the Biodistribution, Target Engagement and Safety of STK-001 in Non-Human Primates That Support the Planned Clinical Development of STK-001 for the Treatment of Dravet Syndrome

    STK-001 showed distribution throughout the brain after a single intrathecal injection; Target engagement and increased Nav1.1 protein expression were observed throughout the cortex Safety findings showed STK-001 to

  5. Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome

    New data from electroencephalography (EEG) recordings showed 76% of Dravet syndrome (DS) mice treated with STK-001 were seizure free compared to 48% of placebo-treated mice An 80% reduction in the average number of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 trial to be initiated 1H 2020 with data due 2021.
STK-001
Dravet syndrome

Latest News

  1. Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy

    SAN FRANCISCO, Jan. 8, 2020 /PRNewswire/ -- Today BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Invitae Corporation (NYSE:NVTA) announced that Biogen (NASDAQ:BIIB), Encoded Therapeutics, Neurogene, Praxis Precision

  2. Stoke Therapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference

    Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today

  3. Stoke Therapeutics Added to NASDAQ Biotechnology Index

    Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that it has

  4. Stoke Therapeutics Presents Preclinical Data on the Biodistribution, Target Engagement and Safety of STK-001 in Non-Human Primates That Support the Planned Clinical Development of STK-001 for the Treatment of Dravet Syndrome

    STK-001 showed distribution throughout the brain after a single intrathecal injection; Target engagement and increased Nav1.1 protein expression were observed throughout the cortex Safety findings showed STK-001 to

  5. Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome

    New data from electroencephalography (EEG) recordings showed 76% of Dravet syndrome (DS) mice treated with STK-001 were seizure free compared to 48% of placebo-treated mice An 80% reduction in the average number of

  6. Stoke Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference

    Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that Chief

  7. Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting

    -- STK-001 is a potential new disease-modifying medicine for the treatment of Dravet syndrome, a severe and progressive form of genetic epilepsy -- Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company

  8. Stoke Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

    Stoke Therapeutics, Inc., (NASDAQ:STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported financial results for

  9. Stoke Therapeutics to Present at Upcoming Investor Conferences in November

    Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today announced that Chief

  10. Stoke Therapeutics to Present at 2019 Cantor Global Healthcare Conference

    Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive

  11. Stoke Therapeutics Added to Russell 2000 and 3000 Indexes

    Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that it has been added